Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Dogwood Therapeutics ( (DWTX) ) just unveiled an announcement.
On June 18, 2025, Dogwood Therapeutics, Inc. held its annual stockholders meeting, where Amendment No. 2 to the Amended and Restated Equity Incentive Plan was approved. This amendment increases the number of shares reserved for issuance by 108,612, following a 25-for-1 reverse stock split in October 2024. Additionally, all matters, including the election of directors and the ratification of Forvis Mazars, LLP as the independent accounting firm, were approved by the stockholders.
The most recent analyst rating on (DWTX) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Dogwood Therapeutics stock, see the DWTX Stock Forecast page.
Spark’s Take on DWTX Stock
According to Spark, TipRanks’ AI Analyst, DWTX is a Neutral.
Dogwood Therapeutics’ overall stock score reflects its financial challenges typical of early-stage biotech firms, with no revenue and significant reliance on external financing. However, the recent debt conversion strengthens the balance sheet and boosts investor confidence. Technical indicators suggest neutral momentum, with a speculative valuation.
To see Spark’s full report on DWTX stock, click here.
More about Dogwood Therapeutics
Dogwood Therapeutics, Inc. operates in the biotechnology industry, focusing on developing innovative therapeutic solutions. The company offers equity incentive plans as part of its market strategy to attract and retain talent.
Average Trading Volume: 855,122
Technical Sentiment Signal: Sell
Current Market Cap: $9.36M
Learn more about DWTX stock on TipRanks’ Stock Analysis page.